

# William J Liu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2101997/publications.pdf>

Version: 2024-02-01

39  
papers

1,382  
citations

516561

16  
h-index

360920

35  
g-index

39  
all docs

39  
docs citations

39  
times ranked

3392  
citing authors

#	ARTICLE	IF	CITATIONS
1	One-Year Sustained Cellular and Humoral Immunities in Coronavirus Disease 2019 (COVID-19) Convalescents. <i>Clinical Infectious Diseases</i> , 2022, 75, e1072-e1081.	2.9	48
2	Landscapes and dynamic diversifications of B-cell receptor repertoires in COVID-19 patients. <i>Human Immunology</i> , 2022, 83, 119-129.	1.2	17
3	Immune response pattern across the asymptomatic, symptomatic and convalescent periods of COVID-19. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2022, 1870, 140736.	1.1	7
4	A COVID-19 T-Cell Response Detection Method Based on a Newly Identified Human CD8 <sup>+</sup> T Cell Epitope from SARS-CoV-2 in Hubei Province, China, 2021. <i>China CDC Weekly</i> , 2022, 4, 83-87.	1.0	4
5	Intra-host variation and evolutionary dynamics of adenoviruses correlate to neutrophils in infected patients. <i>Journal of Medical Virology</i> , 2022, , .	2.5	0
6	Long-Lasting Virus-Specific T Cell Response with Divergent Features in Self-Resolved and Chronic Hepatitis C Virus Patients 35 Years Postinfection. <i>ImmunoHorizons</i> , 2022, 6, 191-201.	0.8	0
7	Pneumonia Severity and Phase Linked to Virus-Specific T Cell Responses with Distinct Immune Checkpoints during pH1N1 Infection. <i>Journal of Immunology</i> , 2022, , j2101021.	0.4	0
8	An adjusted ELISpot-based immunoassay for evaluation of SARS-CoV-2-specific T-cell responses. <i>Biosafety and Health</i> , 2022, 4, 179-185.	1.2	1
9	A CRISPR/Cas12a-empowered surface plasmon resonance platform for rapid and specific diagnosis of the Omicron variant of SARS-CoV-2. <i>National Science Review</i> , 2022, 9, .	4.6	56
10	Cover Image, Volume 94, Number 8, August 2022. <i>Journal of Medical Virology</i> , 2022, 94, .	2.5	0
11	Sustained abnormality with recovery of COVID-19 convalescents: a 2-year follow-up study. <i>Science Bulletin</i> , 2022, 67, 1556-1561.	4.3	5
12	Stability and Structure of Bat Major Histocompatibility Complex Class I with Heterologous $\beta_2$ -Microglobulin. <i>Journal of Visualized Experiments</i> , 2021, , .	0.2	2
13	A Novel Potentially Recombinant Rodent Coronavirus with a Polybasic Cleavage Site in the Spike Protein. <i>Journal of Virology</i> , 2021, 95, e0117321.	1.5	16
14	Peptide Presentations of Marsupial MHC Class I Visualize Immune Features of Lower Mammals Paralleled with Bats. <i>Journal of Immunology</i> , 2021, 207, 2167-2178.	0.4	3
15	A Tale of Two Cities: From Influenza HxNy to SARS-CoV-z. <i>China CDC Weekly</i> , 2021, 3, 1052-1056.	1.0	6
16	Single-Cell Sequencing of Peripheral Mononuclear Cells Reveals Distinct Immune Response Landscapes of COVID-19 and Influenza Patients. <i>Immunity</i> , 2020, 53, 685-696.e3.	6.6	299
17	Strict Assembly Restriction of Peptides from Rabbit Hemorrhagic Disease Virus Presented by Rabbit Major Histocompatibility Complex Class I Molecule RLA-A1. <i>Journal of Virology</i> , 2020, 94, .	1.5	5
18	Elevated plasma levels of selective cytokines in COVID-19 patients reflect viral load and lung injury. <i>National Science Review</i> , 2020, 7, 1003-1011.	4.6	202

#	ARTICLE	IF	CITATIONS
19	Itâ€™s not just science: Challenges for public health intervention in Ebola epidemics in the Democratic Republic of Congo. <i>Science China Life Sciences</i> , 2020, 63, 1079-1081.	2.3	4
20	Convincing the confidence to conquer COVID-19: From epidemiological intervention to laboratory investigation. <i>Biosafety and Health</i> , 2020, 2, 185-186.	1.2	16
21	Divergent Peptide Presentations of HLA-A*30 Alleles Revealed by Structures With Pathogen Peptides. <i>Frontiers in Immunology</i> , 2019, 10, 1709.	2.2	12
22	Peptide presentation by bat MHC class I provides new insight into the antiviral immunity of bats. <i>PLoS Biology</i> , 2019, 17, e3000436.	2.6	23
23	Salt bridge-forming residues positioned over viral peptides presented by MHC class I impacts T-cell recognition in a binding-dependent manner. <i>Molecular Immunology</i> , 2019, 112, 274-282.	1.0	5
24	Comprehensive Clinical and Laboratory Follow-up of a Female Patient With Ebola Virus Disease: Sierra Leone Ebola Virus Persistence Study. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz068.	0.4	12
25	Recombinant Chimpanzee Adenovirus Vaccine AdC7-M/E Protects against Zika Virus Infection and Testis Damage. <i>Journal of Virology</i> , 2018, 92, .	1.5	72
26	Evaluation of Zika Virus-specific T-cell Responses in Immunoprivileged Organs of Infected <i>lfnar1</i> Mice. <i>Journal of Visualized Experiments</i> , 2018, , .	0.2	5
27	Limited Cross-Linking of 4-1BB by 4-1BB Ligand and the Agonist Monoclonal Antibody Utomilumab. <i>Cell Reports</i> , 2018, 25, 909-920.e4.	2.9	33
28	An Invariant Arginine in Common with MHC Class II Allows Extension at the C-Terminal End of Peptides Bound to Chicken MHC Class I. <i>Journal of Immunology</i> , 2018, 201, 3084-3095.	0.4	19
29	CD8 + T-Cell Response-Associated Evolution of Hepatitis B Virus Core Protein and Disease Progress. <i>Journal of Virology</i> , 2018, 92, .	1.5	12
30	Prolonged Evolution of Virus-Specific Memory T Cell Immunity after Severe Avian Influenza A (H7N9) Virus Infection. <i>Journal of Virology</i> , 2018, 92, .	1.5	25
31	Serological Investigation of Laboratory-Confirmed and Suspected Ebola Virus Disease Patients During the Late Phase of the Ebola Outbreak in Sierra Leone. <i>Virologica Sinica</i> , 2018, 33, 323-334.	1.2	7
32	Heterosubtypic Protections against Human-Infecting Avian Influenza Viruses Correlate to Biased Cross-T-Cell Responses. <i>MBio</i> , 2018, 9, .	1.8	25
33	Protective T Cell Responses Featured by Concordant Recognition of Middle East Respiratory Syndrome Coronavirusâ€‘Derived CD8+ T Cell Epitopes and Host MHC. <i>Journal of Immunology</i> , 2017, 198, 873-882.	0.4	42
34	Hemagglutinin-specific CD4 + T-cell responses following 2009-pH1N1 inactivated split-vaccine inoculation in humans. <i>Vaccine</i> , 2017, 35, 5644-5652.	1.7	10
35	T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV. <i>Antiviral Research</i> , 2017, 137, 82-92.	1.9	314
36	The persistent prevalence and evolution of cross-family recombinant coronavirus GCCDC1 among a bat population: a two-year follow-up. <i>Science China Life Sciences</i> , 2017, 60, 1357-1363.	2.3	22

#	ARTICLE	IF	CITATIONS
37	Human T-cell immunity against the emerging and re-emerging viruses. Science China Life Sciences, 2017, 60, 1307-1316.	2.3	21
38	The triphibious warfare against viruses. Science China Life Sciences, 2017, 60, 1295-1298.	2.3	8
39	Cross-immunity Against Avian Influenza A(H7N9) Virus in the Healthy Population Is Affected by Antigenicity-Dependent Substitutions. Journal of Infectious Diseases, 2016, 214, 1937-1946.	1.9	24